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ABSTRACT OF THESIS

ASSESSING THE TEMPORAL RELATIONSHIP BETWEEN CHANGES IN
NEUROTICISM AND SYMPTOM IMPROVEMENT IN THE UNIFIED PROTOCOL
Neuroticism is defined as the tendency to experience frequent and intense negative
emotions accompanied by the belief that one could not cope adequately in response to
stress. Neuroticism is associated with the development and maintenance of a range of
emotional disorders (e.g., anxiety disorders, depression) and targeting this trait in treatment
(rather than symptoms) may represent a more efficient approach to care. However,
researchers have rarely measured neuroticism and symptoms frequently enough to
establish temporal precedence between these dimensions. The present study is a secondary
analysis that examined the temporal relationship between neuroticism and anxiety and
depressive symptoms during a clinical trial of the Unified Protocol (UP), a treatment
developed to address neuroticism. Participants (N = 38) meeting DSM-5 criteria for a
primary emotional disorder completed six weekly sessions of the UP. We hypothesized
that treatment with the UP will result in significant reductions in neuroticism and that
changes in neuroticism would precede and predict changes in anxiety and depressive
symptoms. Results suggest that within-person session-to-session changes in neuroticism
precede and predict next session anxiety, but not depression. These findings add to the
limited research assessing the temporal relationship between personality change and
symptom change.
KEYWORDS: neuroticism, Unified Protocol
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CHAPTER 1. INTRODUCTION
1.1

Background
Neuroticism is defined as the tendency to experience frequent and intense negative

emotions accompanied by the belief that one could not cope adequately in response to
stress (Barlow, Ellard, et al., 2014). According to Barlow’s triple vulnerability theory of
emotional disorders, the neurotic temperament develops as a result of a bidirectional
interaction between a general biological vulnerability (i.e., heritable genetic contributions)
and a general psychological vulnerability (i.e., early life experiences that promote a
heightened sense of unpredictability and uncontrollability; Barlow, Ellard, et al., 2014).
The third vulnerability in Barlow’s model, the specific psychological vulnerability (i.e.,
learning experiences that predispose distress in response to particular stimuli [e.g., physical
sensations in panic disorder, intrusive cognitions in obsessive-compulsive disorder]), may
explain why one disorder emerges over another. Research suggests that maladaptive
responses (i.e., avoidance, perceiving emotions as intolerable) to emotional experiences
often observed in individuals with high neuroticism paradoxically serve to increase and
maintain negative affect and emotional disorder symptoms (Barlow et al., 2014).
Neuroticism has consistently emerged as a transdiagnostic risk factor for various
forms of psychopathology (Andrews, 1996; Barlow, Sauer-Zavala, et al., 2014; Clark et
al., 1994; Khan et al., 2005; Krueger & Markon, 2006; Sher & Trull, 1994; Weinstock &
Whisman, 2006). For example, a meta-analysis of 33 population-based samples found large
associations between neuroticism and anxiety, mood, somatoform, schizophrenia, and
eating disorders (Malouff et al., 2005). There is also evidence that neuroticism
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prospectively predicts the development of mental health difficulties; for example,
longitudinal twin studies have demonstrated that neuroticism predicts the onset of major
depressive episodes (Fanous et al., 2007; Kendler et al., 1993). This trait is also
prospectively associated with the onset of generalized anxiety disorder, social phobia, and
specific phobia (e.g., Goldstein et al., 2018). Additionally, there is evidence to suggest that
neuroticism is associated with comorbidity, accounting for 20-40% of the covariance
among internalizing disorders (Khan et al., 2005; Brown, 2007).
Neuroticism is also linked with a host of other negative outcomes such as higher
divorce rates, increased treatment seeking, and negative physical outcomes, beyond what
can be accounted for by specific symptoms or formal diagnoses (Goodwin et al., 2006;
Lahey, 2009; Suls & Bunde, 2005; Smith & MacKenzie, 2006). For example, in a sample
of primary care patients with depression, neuroticism accounted for significant variation in
health outcomes (i.e., disability, pain, somatization) independent of demographics, chronic
disease, and psychiatric diagnoses. Moreover, when controlling for neuroticism,
depression did not predict poor physical health outcomes (Russo et al., 1997). Because
neuroticism is associated with the development and maintenance of a range of emotional
disorders (e.g., anxiety disorders, depression) and negative health outcomes, targeting this
trait in treatment (rather than symptoms) may represent a more efficient approach to care
(Goodwin et al., 2006; Lahey, 2009; Suls & Bunde, 2005).
1.1.1 Malleability of Neuroticism
Although personality traits have long been considered stable and inflexible
(American Psychiatric Association, 2013), there is increasing evidence that neuroticism
changes over time and is responsive to treatment. For example, age-related decreases in

2

neuroticism have been observed in the general population (Eaton et al., 2011; Roberts &
Mroczek, 2008), although the degree of change varies by individual (Helson et al., 2002;
Mroczek & Spiro, 2003; Small et al., 2003). Additionally, a recent meta-analysis suggests
that personality traits change over the course of relatively brief treatment, and the degree
of change is influenced by principal diagnosis (Roberts et al., 2017). Specifically,
individuals with principal anxiety disorders showed greater decreases in neuroticism and
greater increases in extraversion than those with principal depressive, substance use and
eating disorders, irrespective of the type of treatment administered.
It is worth noting, however, that the studies included in the Roberts et al. (2017)
meta-analysis used symptom-focused treatments (rather than treatments targeting
neuroticism, specifically) and measures of personality traits were a secondary outcome. It
is also important to consider the ability of our personality measures to capture trait change
independent from symptom change. The state-artifact position posits that changes observed
in neuroticism (and other personality traits) following treatment may reflect state-level
fluctuations that are accounted for by symptom improvement, and that what looks like trait
change is actually a temporary state change reflecting imperfect measures (Sauer-Zavala
& Barlow, 2021). Recently, statistical techniques have been employed to directly control
for the role of symptoms when measuring change in neuroticism over time (e.g., Curran
and Bauer, 2011; Fournier et al., 2019).
Despite overall decreases in neuroticism during treatment, intervention effects on
this trait have been mixed across individual studies (e.g., Davenport et al., 2010; Tang et
al., 2009). For example, Tang and colleagues (2009) compared the effects of cognitive
therapy (CT), selective serotonin reuptake inhibitors (SSRIs), and a placebo on neuroticism
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in a sample of adult patients with depression. They found that CT and SSRIs significantly
reduced neuroticism compared to the placebo group; however, when controlling for
depression, decreases in neuroticism were only maintained for those in the SSRI group. In
contrast, when controlling for neuroticism, decreases in depressive symptoms were not
significantly larger in the SSRI group, relative to the placebo group. Taken together, these
results suggest that acute reductions in neuroticism, over the course of treatment, may
require an intervention that exerts a specific effect on this trait; indeed, Tang et al (2009)
demonstrated that SSRIs have a unique effect on neuroticism, whereas CT does not. Other
medication studies have also found a specific effect of SSRIs on negative emotionality that
did not extend to changes in positive affect (Knutson et al., 1998).
1.1.2 Targeting Neuroticism in Treatment
Emerging research suggests that behavioral interventions specifically designed to
target neuroticism may be associated with more robust reductions in this trait (e.g., SauerZavala et al., 2020; Armstrong & Rimes, 2016). For example, the Unified Protocol for
Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al., 2018) is a cognitivebehavioral intervention that was developed to engage neuroticism by aiming to reduce
aversive reactivity (i.e., perceiving emotions as intolerable, efforts to reduce or escape
emotions, anxiety sensitivity) to strong emotional experiences. The UP consists of five core
modules aimed at extinguishing distress in response to strong emotional experiences.
Specifically, by encouraging an approach-oriented stance toward emotions, the UP may
reduce the use of avoidant coping strategies that have been shown to increase the frequency
and intensity of negative emotions (Rassin et al., 2000; Wegner et al., 1987). Sustained
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changes in the frequency and intensity of negative emotions may constitute trait change
(see Magidson et al., 2017) in neuroticism.
Indeed, the UP has shown efficacy in reducing symptoms of anxiety and depressive
disorders (Barlow et al., 2017; Boswell et al., 2014; Ellard et al., 2012; Farchione et al.,
2012) as well as reducing the frequency of negative reactivity to emotions (Sauer-Zavala
et al., 2012). Additionally, treatment with the UP showed significant within-person changes
in extraversion and neuroticism, such that individuals treated with the UP evidenced
significant increases in extraversion and decreases in neuroticism from pre- to posttreatment (Carl et al., 2014). These trait changes were associated with improvements in
symptoms, functioning, and quality of life. More recently, the UP has been shown to reduce
neuroticism to a greater degree than symptom-focused cognitive behavioral therapy (CBT)
and a waitlist control (Sauer-Zavala et al., 2020). This trial found that the greatest
difference in neuroticism decreases between the UP and CBT groups were seen in the last
four treatment sessions.
1.2

Current Study
Despite ample evidence underscoring the relationship between neuroticism and

psychopathology, along with growing support for the notion that this trait can be engaged
in treatment, it is important to understand whether change in neuroticism can serve as a
mechanism predicting symptom improvement. Research suggests that personality trait
change precedes change in personality disorder symptoms, whereas symptom
improvements do not lead to subsequent change in personality traits (Warner et al., 2004).
However, these findings have not been replicated in the context of emotional disorders
(i.e., anxiety and depressive disorders). Indeed, researchers have rarely measured
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neuroticism and symptoms frequently enough to establish temporal precedence regarding
order of change. In a recent trial testing personalized skill sequencing with the UP (SauerZavala et al., under review), participants completed measures of neuroticism and anxiety
and depressive symptoms prior to weekly therapy sessions. The present study, a secondary
analysis from Sauer-Zavala et al. (under review), examined the temporal relationship
between decreases in neuroticism and improvement in anxiety and depressive symptoms.
We hypothesized that participants would demonstrate significant reductions in neuroticism
across treatment, and that changes in this trait will precede and predict changes in anxiety
and depressive symptoms.
To strengthen the conclusions that can be drawn from this study, we also tested two
alternative models. First, we explored whether reductions in anxiety and depressive
symptoms precede and predict improvements in neuroticism to account for trait change in
neuroticism covarying with change in anxiety and depression. Additionally, we tested
whether changes in aversive reactivity significantly predict change in neuroticism which
subsequently predict change in anxiety and depressive symptoms. It is possible that
decreased distress in response to emotions occurs first, which in turn decreases the reliance
on avoidant coping strategies that maintain both neuroticism and emotional disorder
symptoms.
Additionally, we capitalized on the design of the parent study (i.e., Sauer-Zavala et
al., under review) to determine whether change in neuroticism differs as a function of
treatment length or sequencing of skills presented. In the parent study, participants were
randomly assigned to receive modules of the UP in an order that prioritized patient
strengths, compensated for weaknesses, or in the standard published order. Following the

6

fifth therapy session, a secondary randomization assigned participants to either discontinue
treatment after their sixth session (brief treatment condition) or complete the full twelve
sessions (full treatment condition). We explored whether (a) participants in the brief
condition maintain gains garnered across the first six sessions, continue to improve, or
worsen during the follow-up period, (b) participants in the full condition continue to
improve across the entire 12 sessions. Previous research suggests that most of the change
in neuroticism as a function of intervention occurs early and that interventions longer than
eight weeks do not invoke greater change (Roberts et al., 2017); thus, we hypothesized that
there would be no difference in neuroticism change as a function of treatment length.
Additionally, we explored whether there are changes in the extent to which neuroticism
improves as a function of skill sequencing condition; given that there were no differences
across conditions on the primary symptom outcomes (Sauer-Zavala et al., under review),
we hypothesized that there will be no difference in change in neuroticism.
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CHAPTER 2. METHOD
2.1

Participants
A subsample of participants (N = 38, Mage = 34.9, 70% female, 81% Caucasian,

2.7% Latinx, 81.1% heterosexual) were drawn from a sequential multiple assignment
randomized trial (SMART) of the Unified Protocol (UP; Sauer-Zavala et al., under review)
for secondary data analyses related to the present aims. Individuals were eligible for the
parent trial if they met Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5;
American Psychiatric Association, 2013) criteria for an emotional disorder (i.e., anxiety,
depressive [major depression, persistent depression, or premenstrual dysmorphic
disorders], obsessive-compulsive and related, or trauma and stressor-related disorder).
Individuals were excluded from participation if they endorsed diagnoses or symptoms
requiring clinical prioritization or hospitalization (i.e., mania within the past year, acute
suicide risk, substance use disorder not in early remission, or the lifetime presence of
psychotic features [i.e., hallucinations or delusions]). Patients were also excluded if they
received five or more sessions of CBT within the last five years. Anyone receiving other
psychotherapy focused on an emotional disorder agreed to discontinue while participating
in the study. Individuals taking psychotropic medication (N = 9 in the present subsample)
were asked to maintain their current dosages while participating in the study and be stable
on their current medications for one month prior to starting the study. Participants who
completed at least two weekly self-report measures of neuroticism, anxiety symptoms, and
depressive symptoms within the first seven weeks of the parent trial were included in this
subsample.

2.2

Procedure
All procedures were approved by our university’s Institutional Review Board.

After an initial phone screen, likely eligible participants were invited to complete a baseline
assessment that consisted of obtaining informed consent1, administering a clinician-rated
diagnostic assessment to confirm eligibility, and completing a self-report battery. Once
eligibility was confirmed, participants were randomly assigned to receive modules of the
UP in the standard, published order (standard condition), in an order that prioritized patient
strengths (strengths condition), or in an order that compensated for skill deficits
(weaknesses condition). Skill strengths and deficits were determined by evidence-based
questionnaires selected to measure the skills targeted by each UP module. For example, the
Southampton Mindfulness Questionnaire (Chadwick et al., 2008) was used to assess
competence with the Mindful Emotion Awareness module (see Sauer-Zavala et al., under
review for further detail). Total scores for each measure were converted into standard
scores which were used to rank order the modules from greatest skill deficit to strongest
strength.
Following the fifth therapy session, participants completed a second major
assessment (mid-treatment assessment for those in the full condition; a clinician-rated
diagnostic assessment corresponding to diagnoses assigned at baseline and self-report
battery) and underwent a second-stage randomization to determine if they would terminate
treatment after their sixth session (brief treatment condition) or continue for the full twelve
sessions (full treatment condition). Participants in the full treatment condition received all
1

At the beginning of the study, written informed consent was obtained. When study procedures moved
online due to the COVID-19 pandemic, verbal consent was obtained.
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five core modules of the UP while patients in the brief condition received two or three
modules depending on the order in which the modules were presented. Individuals in the
brief condition receiving modules in the standard order completed modules 1
(understanding emotions), 2 (mindfulness), and 3 (cognitive flexibility). Of the participants
in the subsample, 36.8% received module 1, 63.2% received module 2, 63.2% received
module 3, 68.4% received module 4 (countering emotional behaviors) and 34.2% received
module 5 (tolerating physical sensations) in the first six sessions. All participants
completed weekly self-report questionnaires and a follow-up assessment (DIAMOND
modules corresponding to baseline diagnoses and self-report questionnaires) after the 12th
week of the study, regardless of condition (brief or full). Participants were compensated
$25 for each additional assessment they completed after baseline (i.e., compensated up to
$50 total).
2.3

Measures
2.3.1 Diagnostic Assessment
The Diagnostic Interview for Anxiety, Mood, and OCD and Related

Neuropsychiatric Disorders (DIAMOND; Tolin et al. 2013) is a semi-structured, clinicianrated interview that assesses DSM-5 diagnostic criteria for anxiety, depressive, bipolar,
obsessive-compulsive, trauma- and stressor-related disorders, and schizophrenia spectrum
and other psychotic disorders. Modules of the DIAMOND were administered at baseline
to determine the presence of an anxiety, depressive, or related disorder for inclusion and
the absence of manic/hypomanic episodes within the past year, schizophrenia spectrum, or
other psychotic disorders. Subsequent follow-up assessments included only the
DIAMOND modules corresponding to diagnoses endorsed at baseline. The DIAMOND
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showed test-retest reliability ranging from good (κ = .59) to excellent (κ = 1) and interrater reliability ranging from very good (κ = .62) to excellent (κ = 1) for all diagnoses in
the validation sample (Tolin et al., 2016). In the SMART trial from which the present data
were drawn, inter-rater reliability among certified graduate student assessors was excellent
for the 20% of tapes randomly selected for reliability testing (Krippendorff’s as: .91-1.00;
median = 1.00).
2.3.2

Symptom Severity

The Overall Anxiety Severity and Impairment Scale (OASIS; Norman et al., 2006)
is a five-item measure assessing the severity of anxiety symptoms and associated
impairment of functioning over the last week on a five-point Likert scale ranging from 0 (I
didn’t feel anxious) to 4 (constantly anxious). Higher scores indicate greater functional
impairment and symptom severity. Participants completed the OASIS at each major
assessment (i.e., baseline, mid-treatment, and follow-up) and prior to each therapy session.
Scores on the five items of the OASIS showed strong internal consistency (α = .80) and
one month test-retest reliability (κ = .82; Norman et al., 2006). Items demonstrated
excellent internal consistency in the present subsample at baseline (McDonald’s ω = .80).
The Overall Depression Severity and Impairment Scale (ODSIS; Bentley et al.,
2014) is a five-item measure assessing the severity of depressive symptoms and associated
impairment of functioning over the last week on a five-point Likert scale ranging from 0 (I
didn’t feel depressed) to 4 (constantly depressed). Higher scores indicate greater functional
impairment and symptom severity. Participants completed the ODSIS at each major
assessment and prior to each therapy session. The five items of the ODSIS showed
excellent internal consistency (α = .96) and strong two month test-retest reliability in
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clinical (κ = .73) and non-clinical samples (κ = .75; Bentley et al., 2014). Items
demonstrated excellent internal consistency in the present subsample at baseline
(McDonald’s ω = .92).
2.3.3

Neuroticism

The NEO Five Factor Inventory (NEO-FFI; Costa & McCrae, 1992) is an
abbreviated version of the Revised NEO Personality Inventory (NEO-PI-R; Costa &
McCrae, 1992). Specifically, the NEO-FFI is a 60-item self-report measure of the five
factor

domains

of

personality

(i.e.,

neuroticism,

extraversion,

agreeableness,

conscientiousness, and openness to experience) rated on a 5-point Likert scale from 1
(strongly disagree) to 5 (strongly agree). Participants completed the neuroticism scale
(NEO-FFI-N) prior to each therapy session. The NEO-FFI-N has shown strong internal
consistency (α = .84) and two week test-retest reliability (r = .89; Robins et al., 2001).
Items demonstrated excellent internal consistency in the present subsample at baseline
(McDonald’s ω = .82).
2.3.4

Aversive Reactivity

The Multidimensional Experiential Avoidance Questionnaire (MEAQ; Gámez et
al., 2011) is 62-item self-report measure of experiential avoidance rated on a 6-point Likert
scale (ranging from strongly disagree to strongly agree). Experiential avoidance is the
tendency to avoid negative internal experiences (i.e., negative emotionality) that underlies
aversive reactivity, a transdiagnostic mechanism thought to maintain emotional disorders.
The Distress Aversion subscale examines negative evaluations towards or nonacceptance
of distress which may be particularly related to change in neuroticism. Participants
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completed the MEAQ-DA prior to each therapy session. The MEAQ-DA has shown strong
convergent validity (r = .62) and internal consistency (α = .85).
2.4

Data Analytic Plan
We first examined whether the subsample of patients included in the present study

(n = 38) differed from those excluded from analyses but included in the primary study (n
= 21). We used an independent samples t-test to determine if the two groups differed
according to age, chi-squared goodness of fit tests to determine if the groups differed in
gender identity, marital status, and sexual orientation. Fisher’s exact test was used to
address the small cell sizes in these chi-square comparisons. Finally, Wilcoxon-MannWhitney U tests were used to determine if the two groups differed according to education
level and family income.
Next, we examined whether treatment with the UP was associated with significant
decreases in neuroticism. Given the nested structure of the data (i.e., sessions within
patients), we used hierarchical linear modeling (HLM) in SAS Version 9.4 to test this
effect. We regressed neuroticism scores on session number, adding ordering condition as
a covariate, including random intercepts. We then used piecewise linear mixed-effects
models with a linear spline to examine change in neuroticism as a function of treatment
length conditions (brief and full). Our linear spline demarcated session six as the timepoint
in which we expected the slope of change in neuroticism to vary across treatment length
conditions; given that participants in the brief condition discontinued treatment after
session six, it would be expected that slopes of their neuroticism scores may be different
than those who continued treatment for the remaining six weeks. Specifically, we fit a
linear model for each combination of ordering and treatment duration condition (e.g.,
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standard order and brief treatment, standard order and full treatment, etc.). We used
ordering condition (strengths, weakness, standard) as a moderator in these models. Lastly,
we assessed the slopes of change in neuroticism among participants in the two treatment
length conditions (i.e., brief and full) before and after session six to determine if
participants in the brief condition continued to make treatment gains (i.e., decreases in
neuroticism) after discontinuing care and if participants in the full condition saw
neuroticism decreases across all twelve sessions.
To assess whether changes in neuroticism precede and predict changes in
depressive and anxiety symptoms, we again used HLM, analyzing data collected from
weeks 1-7 only. Because neuroticism and anxiety and depressive symptoms were assessed
one week following each therapy sessions (to allow for homework practice), data from
session seven (reflecting improvement following session 6) were included. Participants
who provided data on at least two occasions during weeks 1-7 were included in the
analyses. We used restricted maximum likelihood estimation to obtain unbiased estimates
of the variance components.
We first disaggregated participants’ neuroticism scores into between- and withinperson variability in line with Curran and Bauer’s (2011) recommendations. Betweenperson variability in neuroticism was determined by calculating each participant’s mean
neuroticism score across sessions 1-7, calculating a grand mean of the sample, and
subtracting the grand mean from each participant’s mean score. Within-person variability
in neuroticism was calculated by subtracting each participant’s mean score across sessions
1-7 from their raw neuroticism score at each session. This process was repeated for OASIS,
ODSIS, and MEAQ-DA scores from sessions 1-7. We then created a lagged variable for
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each within- and between-person variable with a lag of one session. We then regressed the
target variable (e.g., depression) at session t on between- and within-person neuroticism at
session t and the target symptom at t–1 (to control for current-session symptom severity).
To test for bidirectional relations (i.e., that changes in anxiety and depressive
symptoms predict session-to-session changes in neuroticism), we regressed neuroticism
scores at session t on between- and within-person anxiety at session t and neuroticism
scores at session t–1, using the same model specifications as above. We then replaced
anxiety with depression in a separate model.
To test an alternative explanation for the UP’s association with neuroticism and
symptom severity, we used the MLmed macro (Rockwood, 2017) in SPSS Version 27 to
determine whether changes in aversive reactivity significantly predict change in
neuroticism which subsequently predict change in anxiety and depressive symptoms.
Specifically, we analyzed a within-person mediation model in which aversive reactivity (x)
predicts next-session neuroticism (m) which then predicts anxiety and depression (y), in
separate models. The MLmed macro performs within-group centering of lower-level
predictor variables and stacking the data as recommended by Bauer and colleagues (2006).
Additionally, indirect effects include Monte Carlo confidence intervals around withingroup effects.
Finally, using G*Power Version 3.1 (Faul et al., 2009) to conduct a sensitivity to
power analysis to calculate the effect size our sample was powered to detect, assuming a
= .05, power = .80, n = 38, with 1 predictor, we were powered to detect small-to-medium
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sized between-person effects (f2 ³ .22). Using Lafit and colleagues’ (2021) Shiny app, we
were powered to detect small within-person effects (R2 ³ .10).
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CHAPTER 3. RESULTS
3.1

Descriptive Statistics
The sample included in the current study did not differ in age, gender identity,

sexual orientation, education level, marital status, or family income, ps > .08, compared to
those who were included in the parent trial but excluded from this secondary analysis.
Participants included in the present sample provided NEO-FFI entries a total of 491 times:
194 entries were completed by participants in the Strengths condition, 118 entries were
completed by those in the Standard condition, and 183 entries were completed by those in
the Weaknesses condition.

3.2

Changes in Neuroticism Across Treatment
Average neuroticism scores for all participants across time are shown in Figure 1.

Treatment with the UP was associated with significant decreases in neuroticism, such that
neuroticism decreased as sessions progressed across all twelve sessions, B = -.26 SE = .09,
p < .01, 95% CI [--.43, -.08]. Using a linear spline to assess the slope of change in
neuroticism before and after the second-stage randomization at session six revealed a
significant decrease in neuroticism before session six, B = -.38, SE = .16, p = .02, 95% CI
[-.69, -.07], but not after, p > .55. Indeed, the magnitude of change in neuroticism from
session one to session six was small, ESsg = .23, whereas the change in neuroticism from
session six to week twelve2 was minimal, ESsg = .09. However, averaged across sequencing
conditions, participants in the full treatment length condition showed significant decreases

2 Not all participants received the full treatment (12 sessions); however, all participants were asked to
complete questionnaires for all twelve weeks of the study. We use ‘week’ rather than ‘session’ to denote
this discrepancy.
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in neuroticism both before session six, B = -.50, SE = .22, p = .02, 95% CI [-.93, -.08], and
after, B = -.34, SE = .16, p = .04, 95% CI [-.66, -.02]. Those in the brief treatment condition
evidenced decreases in neuroticism prior to session six and increases in neuroticism
following session six, though these changes were not significant, ps > .24. Changes in
neuroticism across treatment length conditions are shown in Figure 2.
Moreover, different patterns in neuroticism change before and after the secondstage randomization were observed as a function of ordering condition. Averaged across
length condition, participants in the Strengths condition showed significant decreases in
neuroticism before session six, B = -.93, SE = .24, p < .01, 95% CI [-1.40, -.45], but not
after, p > .29. By contrast, those receiving modules in the standard order showed significant
decreases in neuroticism following session six, B = -.51, SE = .20, p = .01, 95% CI [-.89, .12], but not before, p > .59. Participants in the ordering condition that compensated for
skill deficits showed a decrease in neuroticism before session six followed by an increase
in neuroticism after session six, though these changes were not significant, ps > .69.
Average changes in neuroticism across module ordering conditions are shown in Figure 3.

3.3

Within-Person Changes in Neuroticism and Symptom Severity
Within-person decreases in neuroticism (i.e., lower than one’s personal average)

were associated with session-to-session decreases in anxiety symptoms, B = .18, SE = .06,
p = .004, 95% CI [.06, .30], but not depression, p = .14. Between-person neuroticism was
unrelated to anxiety, p = .41, and depression, p = .14. By contrast, neither within- nor
between-person anxiety or depression predicted session-to-session changes in neuroticism,
ps > .05. These results suggest that neuroticism uniquely predicts session-to-session
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changes in anxiety symptoms. Session-to-session changes in these models can be seen in
Table 1.
Testing an alternative model to assess whether neuroticism mediates the
relationship between aversive reactivity and change in symptoms, revealed significant
within-person effects of aversive reactivity on neuroticism, B = .29, SE = .03, p < .01 95%
CI [ .23, .35]. Within-person changes in aversive reactivity also significantly predicted
anxiety, B = .11, SE = .02, p < .01, 95% CI [.06, .15], and depression, B = .09, SE = .02, p
< .01, 95% CI [.04, .13]. As noted previously, there was also a significant within-person
effect of neuroticism on anxiety, B = .21, SE = .03, p < .01, 95% CI [.14, .26], but not
between, p > .14. Within-persons, there was a significant indirect effect of aversive
reactivity on anxiety, through neuroticism, B = .06, SE = .01, p < .01, 95% CI [.04, .08].
Neuroticism exhibited a significant effect on depression within-persons, B = .18, SE = .03,
p < .01, 95% CI [.11, .24]. There was a significant indirect effect of aversive reactivity on
depression, through neuroticism within-persons, B = .05, SE = .01, p < .01, 95% CI [.03,
.07].
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Table 1: Session-to-Session Analyses
B

SE

p

95% CI

.18

.06

.00

[.06, .30]

.02

.03

.41

[-.03, .08]

.11

.07

.14

[-.04, .26]

Between-Person Neuroticism

.05

.03

.14

-[.02, .11]

Dependent Variable: Neuroticism
Within-Person Anxiety

.39

.20

.05

[-.00, .78]

Between-Person Anxiety

-.12

.16

.44

[-.44, .19]

Within-Person Depression

-.04

.15

.77

[-.34, .25]

Between-Person Depression

.12

.09

.17

[-.05, .30]

Dependent Variable: Anxiety
Within-Person Neuroticism
Between-Person Neuroticism
Dependent Variable: Depression
Within-Person Neuroticism
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Figure 1: Change in Neuroticism over time
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CHAPTER 4. DISCUSSION
In this secondary analysis, we found that significant decreases in neuroticism
occurred across treatment with the UP, replicating previous findings (e.g., Carl et al., 2014;
Sauer-Zavala et al., 2020). Moreover, the largest amount of change on this trait occurred
prior to session six, supporting Roberts and colleague’s (2017) conclusions that change in
personality traits occurs relatively early during treatment. When examining improvements
as a function of skill sequencing, only those who received UP modules in an order that
prioritized existing skill strengths showed significant decreases in neuroticism before
session six, whereas those who received skills in the standard published order or in a
sequence that prioritized relative deficits did not exhibit early change in this trait. However,
patients who were assigned to the standard order and full treatment conditions did
eventually evidence significant decreases in neuroticism, though these improvements were
not observed until the latter half of treatment. Those who received modules in an order that
compensated for skill weaknesses did not show significant changes in neuroticism.
Although this pattern of results for neuroticism change is in line previous research that
favors the compensation model for treatment personalization (e.g., Cheavens et al., 2012),
there were no differences in degree of symptom improvement as a function of ordering
condition in this study (Sauer-Zavala et al., under review). This contrast of patterns
suggests that neuroticism may not be the only driving force behind symptom change.
With regard to why earlier changes in neuroticism were observed in the
capitalization ordering condition, relative to the standard ordering condition wherein
improvements occurred in the latter half of treatment, it is worth noting that the standard
sequence of the UP begins with two sessions of psychoeducation (i.e., Understanding
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Emotions Module). Although this module provides patients with important foundational
knowledge on the adaptive function of emotions and is associated with robust
improvements in symptoms (Boswell, Anderson, & Barlow, 2014; Sauer-Zavala et al.,
2017), it does not provide an emotion regulation skill per se. It is possible that applying
psychoeducation at the beginning of treatment and delaying skill practice until after session
two may have resulted in lagged decreases in neuroticism. Perhaps the UP modules
administered in the latter half (i.e., after session six) of the standard treatment sequence
target neuroticism more directly than those administered early in treatment. For example,
the goal of the Countering Emotional Behaviors Module is to extinguish distress in
response to emotional experiences; by decreasing this aversive reactivity, the module aims
to reduce the use of avoidant coping strategies that lead to the emotional rebound effects
that may maintain neuroticism. Indeed, previous research suggests that the majority of
change in neuroticism occurs during the Countering Emotional Behaviors module (SauerZavala et al., 2020). Increasing one’s ability to tolerate negative emotional experiences
may decrease neuroticism.
It is important to note, however, that individuals in the capitalization condition
(who demonstrated early change in neuroticism) completed the Countering Emotional
Behaviors module at similar rates to those in the compensation condition (who did not
demonstrate early change) across the first six sessions. However, individuals in the
capitalization condition received the Confronting Physical Sensations modules twice as
frequently as those in the compensation condition. This module focuses on interoceptive
exposures with the goal of reducing distress in response to and increasing tolerance of
physical symptoms (i.e., increased heart rate, hyperventilation). Interoceptive exposures
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have been hypothesized to target anxiety sensitivity, a transdiagnostic construct related to
the development of anxiety disorders (Baillie & Rapee, 2005). Indeed, the Confronting
Physical Sensations module led to significant decreases in anxiety sensitivity which
subsequently led to symptom improvement (Boswell et al., 2013). Researchers have
suggested that increases anxiety sensitivity in response to physiological arousal associated
with anxiety may interfere with imaginal or in vivo exposures for social anxiety, obsessivecompulsive, and generalized anxiety disorders (Boswell et al., 2013). It is possible that the
Confronting Physical Sensations module is necessary for some patients to be able to
tolerate the emotional exposers conducted in the Countering Emotional Behaviors module
and thus evidence significant change in neuroticism following this module.
The Countering Emotional Behaviors and Confronting Physical Sensations
modules aim to reduce distress in response to emotional experiences and physical
sensations, respectively. By targeting distress responses, these modules may be addressing
the same transdiagnostic construct: aversive reactivity. It is possible that change in aversive
reactivity is a mechanism driving change in both neuroticism and symptoms. Indeed, when
examining the effects of aversive reactivity on neuroticism and symptom change, aversive
reactivity showed indirect effects on symptom change through neuroticism. These findings
suggest that aversive reactivity is a core process underscoring neuroticism change, which
subsequently affects symptoms. This further supports the idea that the UP works by
targeting aversive reactivity to negative emotions (Southward & Sauer-Zavala, 2020) and
suggests that this process is a core mechanism underlying both neuroticism and symptoms.
Finally, neuroticism scores below one’s personal average were associated
with next session deceases in anxiety symptoms, but not depression. Conversely, neither
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within- nor between-person changes in anxiety and depression predicted next session
changes in neuroticism. This pattern of results suggest that neuroticism exhibits a unique
effect on session-to-session changes in anxiety. However, the lack of association between
neuroticism and session-to-session changes in depression may be due to the measure used
(NEO-FFI). The neuroticism subscale of the NEO-FFI contains more questions assessing
the anxiety facet of neuroticism than the depression facet. Continued research is needed to
further disentangle symptoms and personality. For example, it is unclear how unique
neuroticism is from anxiety and depression, particularly regarding measures of
neuroticism. The NEO-FFI, for example, contains more questions related to anxiety than
depression. Moreover, it is unclear whether these questions are assessing something totally
unique from anxiety symptoms. Because we cannot completely differentiate neuroticism
from anxiety and depression, it may be that the unique effects of neuroticism on anxiety
found in this study are a result of the measures of neuroticism and anxiety being highly
related.
Despite these limitations, this study adds to the limited research assessing
the temporal relationship between personality change and symptom change. Researchers
have infrequently measured neuroticism and symptoms frequently enough to establish
temporal precedence. The present study adds preliminary evidence that neuroticism
changes before anxiety symptoms. Additionally, this study’s findings suggest that aversive
reactivity changes before neuroticism and may be responsible for symptom change, above
and beyond personality change. Together, these results offer mechanistic targets for
transdiagnostic treatment of emotional disorders.
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